Ventilator-associated pneumonia Market Top Players are:

Merck & Co., Inc. (US), Adenium Biotech ApS (Denmark), AstraZeneca (UK), MedImmune (US), Nabriva Therapeutics AG (Austria).

Get Sample Report @ https://www.marketresearchfuture.com/sample_request/1377 .

Ventilator-Associated Pneumonia (VAP) Market consists of four regions Americas, Europe, Asia Pacific and Middle East & Africa. America is the largest market for Ventilator-associated pneumonia (VAP) whose growth is contributed to increase in prevalence of smoking leading to lung diseases, large number of patients suffering from chronic heart diseases and demand of mechanical ventilators. The market is growing continuously in Europe due to extensive demand of medical devices in hospitals, and increasing healthcare expenditure. Asia Pacific is expected to be the fastest growing market owing to increase in environmental pollution, high incidence of asthma & chronic obstructive pulmonary disease and large patient pool. Moreover, Awareness regarding prevention of hospital acquired infection, pneumonia and quality control measures taken by hospitals for control of nosocomial infection favour the growth of this market. Increasing ageing population and incidence of infectious disease too contribute for the growth of this market in Asia Pacific. On the other hand, the Middle East & Africa region are likely to have a limited but steady growth in the market.

Industry Overview:

Patients in critical care require aid for respiration. Many of them suffer from disease like heart disease which require continuous monitoring by healthcare staff in intensive care unit. Ventilator- associated pneumonia is prevalent among patients admitted to ICUs. It is a significant cause of morbidity and mortality in ICU. This disease results from contaminated pathogen secretions in the lungs. Prolonged use of ventilators in ICU favour the growth of this market. Increase in hospital acquired infection is also another factor contributing for the growth of this market. Prevention of ventilator-associated pneumonia is important to protect the health of patients suffering from life threating diseases.

Get Discount @ https://www.marketresearchfuture.com/check-discount/1377 .

Competitive Analysis:

June, 2016 - AstraZeneca had announced that the European Commission (EC) has granted marketing authorisation for Zavicefta, which a combination antibiotic for the treatment of patients with serious Gram-negative bacterial infections requiring hospitalisation. AstraZeneca is a global, innovation-driven biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas which are respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology and infection and neuroscience. Company operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. As per company reports, hospital-acquired pneumonia (HAP) denotes the development of lung infections after a patient has been hospitalised for a minimum of 48 hours.

However, after 48 hours, the infection develops during the use of incubation and mechanical ventilation, the condition is then called ventilator associated pneumonia (VAP). VAP is generally a severe illness, with patients requiring treatment in the intensive care unit (ICU). The approval includes intravenous use of Zavicefta for the treatment of patients suffering from intra-abdominal infections (cIAI); Complicated urinary tract infections (cUTI), including pyelonephritis; hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP); and, the treatment of aerobic Gram-negative infections in adult patients who have limited treatment options. Zavicefta has been developed in response to the urgent need for new antibiotics to treat serious infections that are becoming increasingly resistant, such as multi-drug resistant P. aeruginosa, carbapenem-resistant Gram-negative pathogens, and ESBL-producing Enterobacteriaceae.

Study Objectives of Ventilator-associated pneumonia Market are:

To provide detailed analysis of the market structure along with forecast for the next 10 years of the various segments and sub-segments of the Ventilator-associated pneumonia (VAP) market.
To provide insights about factors affecting the market growth.
To analyze the Ventilator-associated pneumonia (VAP) market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.
To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
To provide country level analysis of the market with respect to the current market size and future prospective.
To provide country level analysis of the market for segments by type, by application, by end users and its sub-segments.
To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.
To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Ventilator-associated pneumonia (VAP) market.
Request for Table of Contents @ https://www.marketresearchfuture.com/request-toc/1377 .

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: [email protected]